StockData
Immunocore Holdings plc logo

Immunocore Holdings plc (IMCR) stock

IMCRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 7/3014% below fair value
$27.81−1.07 (-3.70%)

Close on Nov 17, 2026Market cap $1.43BP/E –Yield 0.00%

Immunocore operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Immunocore's operating cash flow for the twelve months ending Jun 30, 2026 was -$34.96M, down 204.1% year over year. For fiscal 2025 it was -$10.71M, down 141.1% from the year before. The highest annual figure on record is $26.06M in fiscal 2024.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$10.71M-141.1%
FY2024Dec 31, 2024$26.06M+786.4%
FY2023Dec 31, 2023$2.94M–
FY2022Dec 31, 2022-$49.21M–
FY2021Dec 31, 2021-$143.11M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$15.93M-38.7%
Q1 FY2026Mar 31, 2026-$13.78M-3266.7%
Q4 FY2025Dec 31, 2025-$32.66M–
Q3 FY2025Sep 30, 2025-$4.46M-121.1%
Q2 FY2025Jun 30, 2025$25.96M+10.6%
Q1 FY2025Mar 31, 2025$435.00K–
Q4 FY2024Dec 31, 2024-$13.95M–
Q3 FY2024Sep 30, 2024$21.13M+109.4%
Q2 FY2024Jun 30, 2024$23.47M+52060.0%
Q1 FY2024Mar 31, 2024-$4.59M-143.5%
Q4 FY2023Dec 31, 2023-$17.73M–
Q3 FY2023Sep 30, 2023$10.09M–
Q2 FY2023Jun 30, 2023$45.00K–
Q1 FY2023Mar 31, 2023$10.54M–

More Immunocore figures

See a number that looks wrong?